FINWIRES · TerminalLIVE
FINWIRES

Whitehaven Coal Posts Higher Fiscal Q3 Managed ROM Production

By

Whitehaven Coal (ASX:WHC) said managed run-of-mine (ROM) production reached 9.5 million tonnes in the fiscal third quarter ended March, including 4.1 million tonnes from Queensland and 5.4 million tonnes from New South Wales, according to a Thursday Australian bourse filing.

The company's March quarter 2025 managed ROM was 9.2 million tonnes with total equity sales of produced coal of 6.3 million tonnes, an earlier filing showed.

The company reported March quarter equity sales of produced coal of 6.8 million tonnes.

The company said ROM coal production and coal sales are tracking to be firmly in the upper half of fiscal year 2026 guidance of 37 million tonnes to 41 million tonnes, with unit costs tracking around the midpoint of the AU$130 to AU$145 per tonne guidance range and capital expenditure on track to be around the low end of AU$340 million to AU$440 million.

Net debt stood at AU$600 million at March 31, before a second deferred acquisition payment to BMA of $500 million made on April 2, with refinancing of acquisition debt completed in April via $900 million of senior secured notes and $600 million of bank funding, delivering interest savings of AU$50 million to AU$55 million per year from May, the filing added.

The company remains on track to deliver AU$60 million to AU$80 million of annualized cost savings by June 30, the filing added.

Whitehaven continued its share buyback during the quarter, repurchasing 1.4 million shares for AU$11 million, with 7.7 million shares bought back for AU$56 million in the fiscal year to date, it added.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA